CN118055927A - 一种取代的苯丙酸衍生物及其用途 - Google Patents

一种取代的苯丙酸衍生物及其用途 Download PDF

Info

Publication number
CN118055927A
CN118055927A CN202280066584.5A CN202280066584A CN118055927A CN 118055927 A CN118055927 A CN 118055927A CN 202280066584 A CN202280066584 A CN 202280066584A CN 118055927 A CN118055927 A CN 118055927A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently selected
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280066584.5A
Other languages
English (en)
Chinese (zh)
Inventor
谭亮
董玉琼
刘敏
李姣
李健
张瑱
林晓燕
李云飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Shanghai Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Tuojie Biomedical Technology Co ltd filed Critical Shanghai Tuojie Biomedical Technology Co ltd
Publication of CN118055927A publication Critical patent/CN118055927A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280066584.5A 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途 Pending CN118055927A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111293711 2021-11-03
CN2021112937119 2021-11-03
CN202211033065 2022-08-26
CN2022110330657 2022-08-26
PCT/CN2022/129479 WO2023078333A1 (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途

Publications (1)

Publication Number Publication Date
CN118055927A true CN118055927A (zh) 2024-05-17

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280066584.5A Pending CN118055927A (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途

Country Status (10)

Country Link
US (1) US20250042847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4428129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540183A (cg-RX-API-DMAC7.html)
KR (1) KR20240091010A (cg-RX-API-DMAC7.html)
CN (1) CN118055927A (cg-RX-API-DMAC7.html)
AU (1) AU2022381258A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235992A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005304A (cg-RX-API-DMAC7.html)
TW (1) TW202334116A (cg-RX-API-DMAC7.html)
WO (1) WO2023078333A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119894882A (zh) * 2023-04-21 2025-04-25 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
CN121609698A (zh) * 2026-01-30 2026-03-06 山东京新药业有限公司 一种莫伐培林及中间体的制备方法
WO2026130471A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 吡咯烷衍生物或其盐的制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444710A (zh) * 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
KR20260041098A (ko) * 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) * 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025199298A1 (en) 2024-03-21 2025-09-25 Eli Lilly And Company BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a)
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130347A1 (zh) * 2024-12-17 2026-06-25 上海喆邺生物科技有限公司 一种吡咯烷衍生物及其在药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1962596A (zh) * 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US7705177B2 (en) * 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2708706A1 (en) * 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
KR102720992B1 (ko) 2019-06-07 2024-10-24 일라이 릴리 앤드 캄파니 피롤리딘 화합물
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119894882A (zh) * 2023-04-21 2025-04-25 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
WO2026130471A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 吡咯烷衍生物或其盐的制备方法
CN121609698A (zh) * 2026-01-30 2026-03-06 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Also Published As

Publication number Publication date
EP4428129A1 (en) 2024-09-11
JP2024540183A (ja) 2024-10-31
WO2023078333A1 (zh) 2023-05-11
MX2024005304A (es) 2024-05-17
AU2022381258A1 (en) 2024-05-02
US20250042847A1 (en) 2025-02-06
TW202334116A (zh) 2023-09-01
EP4428129A4 (en) 2025-05-07
WO2023078333A8 (zh) 2023-08-10
KR20240091010A (ko) 2024-06-21
CA3235992A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
JP2024540183A (ja) 置換されたフェニルプロピオン酸誘導体及びその使用
CN114008021B (zh) 吡咯烷化合物
US5545644A (en) Indole derivatives
CN119522225A (zh) 大环衍生物及其应用
US5578612A (en) Indole derivatives
CA3203447A1 (en) Series of piperidine-substituted benzoic acid compounds, and use thereof
JP3993651B2 (ja) シクロプロパクロメンカルボン酸誘導体
WO2024026338A1 (en) N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
JPH11500149A (ja) プロテインキナーゼcインヒビター
US5607951A (en) Indole derivatives
JPH07502265A (ja) 酸化窒素供与体プロドラッグとしての求核試薬−酸化窒素付加物の酸素置換誘導体
KR20250128379A (ko) 보체인자 b의 억제제
KR20260009339A (ko) 지질단백질 화합물의 결정형 및 이의 제조방법
US20240317764A1 (en) Salts and solid forms of a compound having apj receptor activity
JP7701475B2 (ja) アルキルカルボン酸化合物及びその使用
PT93045A (pt) Processo para a preparacao de derivados de pirrolidina e de composicoes farmaceuticas que os contem
JP3588363B2 (ja) キノキサリンジオン類
CN108368118B (zh) 一种取代的稠合咪唑环化合物及其药物组合物
WO2001000616A1 (en) Cholesterol biosynthesis inhibitors containing as the active ingredient aromatic compounds bearing cyclic amino groups
CN116744935B (zh) 苯并氮杂䓬类化合物及其制备方法和医药用途
US20230279002A1 (en) Polymorphs of Crystalline Forms of 3,10-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-9-yl 3-fluorobenzenesulfonate and Salts Thereof
US20260098027A1 (en) Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method
WO2026024591A1 (en) Tryptamine prodrug solid forms
TW202615083A (zh) 環肽類似物及其製備方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111086

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20250506

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Applicant after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Country or region after: China

Address before: Room 103, building 14, 3728 Jinke Road, Pudong New Area pilot Free Trade Zone, Shanghai 201203

Applicant before: Shanghai tuojie Biomedical Technology Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right